Summary
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.
According to APO Research, The global PD-1 and PD-L1 Inhibitors market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for PD-1 and PD-L1 Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of PD-1 and PD-L1 Inhibitors include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for PD-1 and PD-L1 Inhibitors, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of PD-1 and PD-L1 Inhibitors, also provides the sales of main regions and countries. Of the upcoming market potential for PD-1 and PD-L1 Inhibitors, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the PD-1 and PD-L1 Inhibitors sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global PD-1 and PD-L1 Inhibitors market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for PD-1 and PD-L1 Inhibitors sales, projected growth trends, production technology, application and end-user industry.
PD-1 and PD-L1 Inhibitors segment by Company
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA
PD-1 and PD-L1 Inhibitors segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
PD-1 and PD-L1 Inhibitors segment by Application
Solid Tumors
Blood-related Tumors
PD-1 and PD-L1 Inhibitors segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1 and PD-L1 Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-1 and PD-L1 Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1 and PD-L1 Inhibitors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of PD-1 and PD-L1 Inhibitors in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of PD-1 and PD-L1 Inhibitors manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, PD-1 and PD-L1 Inhibitors sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 PD-1 and PD-L1 Inhibitors Market by Type
1.2.1 Global PD-1 and PD-L1 Inhibitors Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.3 PD-1 and PD-L1 Inhibitors Market by Application
1.3.1 Global PD-1 and PD-L1 Inhibitors Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Solid Tumors
1.3.3 Blood-related Tumors
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PD-1 and PD-L1 Inhibitors Market Dynamics
2.1 PD-1 and PD-L1 Inhibitors Industry Trends
2.2 PD-1 and PD-L1 Inhibitors Industry Drivers
2.3 PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges
2.4 PD-1 and PD-L1 Inhibitors Industry Restraints
3 Global Market Growth Prospects
3.1 Global PD-1 and PD-L1 Inhibitors Revenue Estimates and Forecasts (2019-2030)
3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Region
3.2.1 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global PD-1 and PD-L1 Inhibitors Revenue by Region (2019-2024)
3.2.3 Global PD-1 and PD-L1 Inhibitors Revenue by Region (2025-2030)
3.2.4 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2019-2030)
3.3 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts 2019-2030
3.4 Global PD-1 and PD-L1 Inhibitors Sales by Region
3.4.1 Global PD-1 and PD-L1 Inhibitors Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global PD-1 and PD-L1 Inhibitors Sales by Region (2019-2024)
3.4.3 Global PD-1 and PD-L1 Inhibitors Sales by Region (2025-2030)
3.4.4 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 Market Competitive Landscape by Manufacturers
4.1 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers
4.1.1 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers (2019-2024)
4.1.2 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global PD-1 and PD-L1 Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers
4.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers (2019-2024)
4.2.2 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global PD-1 and PD-L1 Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global PD-1 and PD-L1 Inhibitors Sales Price by Manufacturers (2019-2024)
4.4 Global PD-1 and PD-L1 Inhibitors Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global PD-1 and PD-L1 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global PD-1 and PD-L1 Inhibitors Manufacturers, Product Type & Application
4.7 Global PD-1 and PD-L1 Inhibitors Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global PD-1 and PD-L1 Inhibitors Market CR5 and HHI
4.8.2 2023 PD-1 and PD-L1 Inhibitors Tier 1, Tier 2, and Tier 3
5 PD-1 and PD-L1 Inhibitors Market by Type
5.1 Global PD-1 and PD-L1 Inhibitors Revenue by Type
5.1.1 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2019-2030)
5.2 Global PD-1 and PD-L1 Inhibitors Sales by Type
5.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Type (2019-2030) & (L)
5.2.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2030)
5.3 Global PD-1 and PD-L1 Inhibitors Price by Type
6 PD-1 and PD-L1 Inhibitors Market by Application
6.1 Global PD-1 and PD-L1 Inhibitors Revenue by Application
6.1.1 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2019-2030)
6.2 Global PD-1 and PD-L1 Inhibitors Sales by Application
6.2.1 Global PD-1 and PD-L1 Inhibitors Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global PD-1 and PD-L1 Inhibitors Sales by Application (2019-2030) & (L)
6.2.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2030)
6.3 Global PD-1 and PD-L1 Inhibitors Price by Application
7 Company Profiles
7.1 Merck
7.1.1 Merck Comapny Information
7.1.2 Merck Business Overview
7.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Merck PD-1 and PD-L1 Inhibitors Product Portfolio
7.1.5 Merck Recent Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Comapny Information
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
7.2.5 Bristol-Myers Squibb Recent Developments
7.3 Roche
7.3.1 Roche Comapny Information
7.3.2 Roche Business Overview
7.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 Roche PD-1 and PD-L1 Inhibitors Product Portfolio
7.3.5 Roche Recent Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Comapny Information
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
7.4.5 AstraZeneca Recent Developments
7.5 Ono Pharmaceutical
7.5.1 Ono Pharmaceutical Comapny Information
7.5.2 Ono Pharmaceutical Business Overview
7.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
7.5.5 Ono Pharmaceutical Recent Developments
7.6 Regeneron
7.6.1 Regeneron Comapny Information
7.6.2 Regeneron Business Overview
7.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
7.6.5 Regeneron Recent Developments
7.7 Innovent
7.7.1 Innovent Comapny Information
7.7.2 Innovent Business Overview
7.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
7.7.5 Innovent Recent Developments
7.8 Hengrui Medicine
7.8.1 Hengrui Medicine Comapny Information
7.8.2 Hengrui Medicine Business Overview
7.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
7.8.5 Hengrui Medicine Recent Developments
7.9 Junshi Biosciences
7.9.1 Junshi Biosciences Comapny Information
7.9.2 Junshi Biosciences Business Overview
7.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
7.9.5 Junshi Biosciences Recent Developments
7.10 Merck KGaA
7.10.1 Merck KGaA Comapny Information
7.10.2 Merck KGaA Business Overview
7.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Revenue, Price and Gross Margin (2019-2024)
7.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
7.10.5 Merck KGaA Recent Developments
8 North America
8.1 North America PD-1 and PD-L1 Inhibitors Market Size by Type
8.1.1 North America PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2030)
8.1.2 North America PD-1 and PD-L1 Inhibitors Sales by Type (2019-2030)
8.1.3 North America PD-1 and PD-L1 Inhibitors Price by Type (2019-2030)
8.2 North America PD-1 and PD-L1 Inhibitors Market Size by Application
8.2.1 North America PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2030)
8.2.2 North America PD-1 and PD-L1 Inhibitors Sales by Application (2019-2030)
8.2.3 North America PD-1 and PD-L1 Inhibitors Price by Application (2019-2030)
8.3 North America PD-1 and PD-L1 Inhibitors Market Size by Country
8.3.1 North America PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America PD-1 and PD-L1 Inhibitors Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America PD-1 and PD-L1 Inhibitors Price by Country (2019-2030)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe PD-1 and PD-L1 Inhibitors Market Size by Type
9.1.1 Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2030)
9.1.2 Europe PD-1 and PD-L1 Inhibitors Sales by Type (2019-2030)
9.1.3 Europe PD-1 and PD-L1 Inhibitors Price by Type (2019-2030)
9.2 Europe PD-1 and PD-L1 Inhibitors Market Size by Application
9.2.1 Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2030)
9.2.2 Europe PD-1 and PD-L1 Inhibitors Sales by Application (2019-2030)
9.2.3 Europe PD-1 and PD-L1 Inhibitors Price by Application (2019-2030)
9.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
9.3.1 Europe PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe PD-1 and PD-L1 Inhibitors Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 China
10.1 China PD-1 and PD-L1 Inhibitors Market Size by Type
10.1.1 China PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2030)
10.1.2 China PD-1 and PD-L1 Inhibitors Sales by Type (2019-2030)
10.1.3 China PD-1 and PD-L1 Inhibitors Price by Type (2019-2030)
10.2 China PD-1 and PD-L1 Inhibitors Market Size by Application
10.2.1 China PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2030)
10.2.2 China PD-1 and PD-L1 Inhibitors Sales by Application (2019-2030)
10.2.3 China PD-1 and PD-L1 Inhibitors Price by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia PD-1 and PD-L1 Inhibitors Market Size by Type
11.1.1 Asia PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2030)
11.1.2 Asia PD-1 and PD-L1 Inhibitors Sales by Type (2019-2030)
11.1.3 Asia PD-1 and PD-L1 Inhibitors Price by Type (2019-2030)
11.2 Asia PD-1 and PD-L1 Inhibitors Market Size by Application
11.2.1 Asia PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2030)
11.2.2 Asia PD-1 and PD-L1 Inhibitors Sales by Application (2019-2030)
11.2.3 Asia PD-1 and PD-L1 Inhibitors Price by Application (2019-2030)
11.3 Asia PD-1 and PD-L1 Inhibitors Market Size by Country
11.3.1 Asia PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia PD-1 and PD-L1 Inhibitors Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia PD-1 and PD-L1 Inhibitors Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 Middle East, Africa and Latin America
12.1 MEALA PD-1 and PD-L1 Inhibitors Market Size by Type
12.1.1 MEALA PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2030)
12.1.2 MEALA PD-1 and PD-L1 Inhibitors Sales by Type (2019-2030)
12.1.3 MEALA PD-1 and PD-L1 Inhibitors Price by Type (2019-2030)
12.2 MEALA PD-1 and PD-L1 Inhibitors Market Size by Application
12.2.1 MEALA PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2030)
12.2.2 MEALA PD-1 and PD-L1 Inhibitors Sales by Application (2019-2030)
12.2.3 MEALA PD-1 and PD-L1 Inhibitors Price by Application (2019-2030)
12.3 MEALA PD-1 and PD-L1 Inhibitors Market Size by Country
12.3.1 MEALA PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA PD-1 and PD-L1 Inhibitors Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA PD-1 and PD-L1 Inhibitors Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 Value Chain and Sales Channels Analysis
13.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
13.1.1 PD-1 and PD-L1 Inhibitors Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 PD-1 and PD-L1 Inhibitors Production Mode & Process
13.2 PD-1 and PD-L1 Inhibitors Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 PD-1 and PD-L1 Inhibitors Distributors
13.2.3 PD-1 and PD-L1 Inhibitors Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
List of Tables
Table 1. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. PD-1 Inhibitors Major Manufacturers
Table 3. PD-L1 Inhibitors Major Manufacturers
Table 4. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 5. Solid Tumors Major Manufacturers
Table 6. Blood-related Tumors Major Manufacturers
Table 7. PD-1 and PD-L1 Inhibitors Industry Trends
Table 8. PD-1 and PD-L1 Inhibitors Industry Drivers
Table 9. PD-1 and PD-L1 Inhibitors Industry Opportunities and Challenges
Table 10. PD-1 and PD-L1 Inhibitors Industry Restraints
Table 11. Global PD-1 and PD-L1 Inhibitors Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 12. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2019-2024) & (US$ Million)
Table 13. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2025-2030) & (US$ Million)
Table 14. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2019-2024)
Table 15. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2025-2030)
Table 16. Global PD-1 and PD-L1 Inhibitors Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (L)
Table 17. Global PD-1 and PD-L1 Inhibitors Sales by Region (2019-2024) & (L)
Table 18. Global PD-1 and PD-L1 Inhibitors Sales by Region (2025-2030) & (L)
Table 19. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2019-2024)
Table 20. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2025-2030)
Table 21. Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 22. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Manufacturers (2019-2024)
Table 23. Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers (US$ Million) & (2019-2024)
Table 24. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Manufacturers (2019-2024)
Table 25. Global PD-1 and PD-L1 Inhibitors Sales Price (USD/ml) of Manufacturers (2019-2024)
Table 26. Global PD-1 and PD-L1 Inhibitors Key Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 27. Global PD-1 and PD-L1 Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
Table 28. Global PD-1 and PD-L1 Inhibitors Manufacturers, Product Type & Application
Table 29. Global PD-1 and PD-L1 Inhibitors Manufacturers Commercialization Time
Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global PD-1 and PD-L1 Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 32. Global PD-1 and PD-L1 Inhibitors Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 33. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2024) & (US$ Million)
Table 34. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2025-2030) & (US$ Million)
Table 35. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2019-2024)
Table 36. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2025-2030)
Table 37. Global PD-1 and PD-L1 Inhibitors Sales by Type 2019 VS 2023 VS 2030 (L)
Table 38. Global PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 39. Global PD-1 and PD-L1 Inhibitors Sales by Type (2025-2030) & (L)
Table 40. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2024)
Table 41. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2025-2030)
Table 42. Global PD-1 and PD-L1 Inhibitors Price by Type (2019-2024) & (USD/ml)
Table 43. Global PD-1 and PD-L1 Inhibitors Price by Type (2025-2030) & (USD/ml)
Table 44. Global PD-1 and PD-L1 Inhibitors Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 45. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2024) & (US$ Million)
Table 46. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2025-2030) & (US$ Million)
Table 47. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2019-2024)
Table 48. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2025-2030)
Table 49. Global PD-1 and PD-L1 Inhibitors Sales by Application 2019 VS 2023 VS 2030 (L)
Table 50. Global PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 51. Global PD-1 and PD-L1 Inhibitors Sales by Application (2025-2030) & (L)
Table 52. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2024)
Table 53. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2025-2030)
Table 54. Global PD-1 and PD-L1 Inhibitors Price by Application (2019-2024) & (USD/ml)
Table 55. Global PD-1 and PD-L1 Inhibitors Price by Application (2025-2030) & (USD/ml)
Table 56. Merck Company Information
Table 57. Merck Business Overview
Table 58. Merck PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 59. Merck PD-1 and PD-L1 Inhibitors Product Portfolio
Table 60. Merck Recent Development
Table 61. Bristol-Myers Squibb Company Information
Table 62. Bristol-Myers Squibb Business Overview
Table 63. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 64. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Portfolio
Table 65. Bristol-Myers Squibb Recent Development
Table 66. Roche Company Information
Table 67. Roche Business Overview
Table 68. Roche PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 69. Roche PD-1 and PD-L1 Inhibitors Product Portfolio
Table 70. Roche Recent Development
Table 71. AstraZeneca Company Information
Table 72. AstraZeneca Business Overview
Table 73. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 74. AstraZeneca PD-1 and PD-L1 Inhibitors Product Portfolio
Table 75. AstraZeneca Recent Development
Table 76. Ono Pharmaceutical Company Information
Table 77. Ono Pharmaceutical Business Overview
Table 78. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 79. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Portfolio
Table 80. Ono Pharmaceutical Recent Development
Table 81. Regeneron Company Information
Table 82. Regeneron Business Overview
Table 83. Regeneron PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 84. Regeneron PD-1 and PD-L1 Inhibitors Product Portfolio
Table 85. Regeneron Recent Development
Table 86. Innovent Company Information
Table 87. Innovent Business Overview
Table 88. Innovent PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 89. Innovent PD-1 and PD-L1 Inhibitors Product Portfolio
Table 90. Innovent Recent Development
Table 91. Hengrui Medicine Company Information
Table 92. Hengrui Medicine Business Overview
Table 93. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 94. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Portfolio
Table 95. Hengrui Medicine Recent Development
Table 96. Junshi Biosciences Company Information
Table 97. Junshi Biosciences Business Overview
Table 98. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 99. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Portfolio
Table 100. Junshi Biosciences Recent Development
Table 101. Merck KGaA Company Information
Table 102. Merck KGaA Business Overview
Table 103. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2019-2024)
Table 104. Merck KGaA PD-1 and PD-L1 Inhibitors Product Portfolio
Table 105. Merck KGaA Recent Development
Table 106. North America PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2024) & (US$ Million)
Table 107. North America PD-1 and PD-L1 Inhibitors Revenue by Type (2025-2030) & (US$ Million)
Table 108. North America PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 109. North America PD-1 and PD-L1 Inhibitors Sales by Type (2025-2030) & (L)
Table 110. North America PD-1 and PD-L1 Inhibitors Sales Price by Type (2019-2024) & (USD/ml)
Table 111. North America PD-1 and PD-L1 Inhibitors Sales Price by Type (2025-2030) & (USD/ml)
Table 112. North America PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2024) & (US$ Million)
Table 113. North America PD-1 and PD-L1 Inhibitors Revenue by Application (2025-2030) & (US$ Million)
Table 114. North America PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 115. North America PD-1 and PD-L1 Inhibitors Sales by Application (2025-2030) & (L)
Table 116. North America PD-1 and PD-L1 Inhibitors Sales Price by Application (2019-2024) & (USD/ml)
Table 117. North America PD-1 and PD-L1 Inhibitors Sales Price by Application (2025-2030) & (USD/ml)
Table 118. North America PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 119. North America PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 120. North America PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 121. North America PD-1 and PD-L1 Inhibitors Sales by Country (2019 VS 2023 VS 2030) & (L)
Table 122. North America PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024) & (L)
Table 123. North America PD-1 and PD-L1 Inhibitors Sales by Country (2025-2030) & (L)
Table 124. North America PD-1 and PD-L1 Inhibitors Sales Price by Country (2019-2024) & (USD/ml)
Table 125. North America PD-1 and PD-L1 Inhibitors Sales Price by Country (2025-2030) & (USD/ml)
Table 126. US PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 127. Canada PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 128. Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2024) & (US$ Million)
Table 129. Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2025-2030) & (US$ Million)
Table 130. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 131. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2025-2030) & (L)
Table 132. Europe PD-1 and PD-L1 Inhibitors Sales Price by Type (2019-2024) & (USD/ml)
Table 133. Europe PD-1 and PD-L1 Inhibitors Sales Price by Type (2025-2030) & (USD/ml)
Table 134. Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2024) & (US$ Million)
Table 135. Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2025-2030) & (US$ Million)
Table 136. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 137. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2025-2030) & (L)
Table 138. Europe PD-1 and PD-L1 Inhibitors Sales Price by Application (2019-2024) & (USD/ml)
Table 139. Europe PD-1 and PD-L1 Inhibitors Sales Price by Application (2025-2030) & (USD/ml)
Table 140. Europe PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 141. Europe PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 142. Europe PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 143. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2019 VS 2023 VS 2030) & (L)
Table 144. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024) & (L)
Table 145. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2025-2030) & (L)
Table 146. Europe PD-1 and PD-L1 Inhibitors Sales Price by Country (2019-2024) & (USD/ml)
Table 147. Europe PD-1 and PD-L1 Inhibitors Sales Price by Country (2025-2030) & (USD/ml)
Table 148. Germany PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 149. France PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 150. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 151. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 152. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 153. China PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2024) & (US$ Million)
Table 154. China PD-1 and PD-L1 Inhibitors Revenue by Type (2025-2030) & (US$ Million)
Table 155. China PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 156. China PD-1 and PD-L1 Inhibitors Sales by Type (2025-2030) & (L)
Table 157. China PD-1 and PD-L1 Inhibitors Sales Price by Type (2019-2024) & (USD/ml)
Table 158. China PD-1 and PD-L1 Inhibitors Sales Price by Type (2025-2030) & (USD/ml)
Table 159. China PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2024) & (US$ Million)
Table 160. China PD-1 and PD-L1 Inhibitors Revenue by Application (2025-2030) & (US$ Million)
Table 161. China PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 162. China PD-1 and PD-L1 Inhibitors Sales by Application (2025-2030) & (L)
Table 163. China PD-1 and PD-L1 Inhibitors Sales Price by Application (2019-2024) & (USD/ml)
Table 164. China PD-1 and PD-L1 Inhibitors Sales Price by Application (2025-2030) & (USD/ml)
Table 165. Asia PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2024) & (US$ Million)
Table 166. Asia PD-1 and PD-L1 Inhibitors Revenue by Type (2025-2030) & (US$ Million)
Table 167. Asia PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 168. Asia PD-1 and PD-L1 Inhibitors Sales by Type (2025-2030) & (L)
Table 169. Asia PD-1 and PD-L1 Inhibitors Sales Price by Type (2019-2024) & (USD/ml)
Table 170. Asia PD-1 and PD-L1 Inhibitors Sales Price by Type (2025-2030) & (USD/ml)
Table 171. Asia PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2024) & (US$ Million)
Table 172. Asia PD-1 and PD-L1 Inhibitors Revenue by Application (2025-2030) & (US$ Million)
Table 173. Asia PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 174. Asia PD-1 and PD-L1 Inhibitors Sales by Application (2025-2030) & (L)
Table 175. Asia PD-1 and PD-L1 Inhibitors Sales Price by Application (2019-2024) & (USD/ml)
Table 176. Asia PD-1 and PD-L1 Inhibitors Sales Price by Application (2025-2030) & (USD/ml)
Table 177. Asia PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 178. Asia PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 179. Asia PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 180. Asia PD-1 and PD-L1 Inhibitors Sales by Country (2019 VS 2023 VS 2030) & (L)
Table 181. Asia PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024) & (L)
Table 182. Asia PD-1 and PD-L1 Inhibitors Sales by Country (2025-2030) & (L)
Table 183. Asia PD-1 and PD-L1 Inhibitors Sales Price by Country (2019-2024) & (USD/ml)
Table 184. Asia PD-1 and PD-L1 Inhibitors Sales Price by Country (2025-2030) & (USD/ml)
Table 185. Japan PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 186. South Korea PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 187. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 188. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 189. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 190. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 191. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 192. PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 193. MEALA PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2024) & (US$ Million)
Table 194. MEALA PD-1 and PD-L1 Inhibitors Revenue by Type (2025-2030) & (US$ Million)
Table 195. MEALA PD-1 and PD-L1 Inhibitors Sales by Type (2019-2024) & (L)
Table 196. MEALA PD-1 and PD-L1 Inhibitors Sales by Type (2025-2030) & (L)
Table 197. MEALA PD-1 and PD-L1 Inhibitors Sales Price by Type (2019-2024) & (USD/ml)
Table 198. MEALA PD-1 and PD-L1 Inhibitors Sales Price by Type (2025-2030) & (USD/ml)
Table 199. MEALA PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2024) & (US$ Million)
Table 200. MEALA PD-1 and PD-L1 Inhibitors Revenue by Application (2025-2030) & (US$ Million)
Table 201. MEALA PD-1 and PD-L1 Inhibitors Sales by Application (2019-2024) & (L)
Table 202. MEALA PD-1 and PD-L1 Inhibitors Sales by Application (2025-2030) & (L)
Table 203. MEALA PD-1 and PD-L1 Inhibitors Sales Price by Application (2019-2024) & (USD/ml)
Table 204. MEALA PD-1 and PD-L1 Inhibitors Sales Price by Application (2025-2030) & (USD/ml)
Table 205. MEALA PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 206. MEALA PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 207. MEALA PD-1 and PD-L1 Inhibitors Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 208. MEALA PD-1 and PD-L1 Inhibitors Sales by Country (2019 VS 2023 VS 2030) & (L)
Table 209. MEALA PD-1 and PD-L1 Inhibitors Sales by Country (2019-2024) & (L)
Table 210. MEALA PD-1 and PD-L1 Inhibitors Sales by Country (2025-2030) & (L)
Table 211. MEALA PD-1 and PD-L1 Inhibitors Sales Price by Country (2019-2024) & (USD/ml)
Table 212. MEALA PD-1 and PD-L1 Inhibitors Sales Price by Country (2025-2030) & (USD/ml)
Table 213. Mexico PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 214. Brazil PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 215. Israel PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 216. Argentina PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 217. Colombia PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 218. Turkey PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 219. Saudi Arabia PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 220. UAE PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Table 221. Key Raw Materials
Table 222. Raw Materials Key Suppliers
Table 223. PD-1 and PD-L1 Inhibitors Distributors List
Table 224. PD-1 and PD-L1 Inhibitors Customers List
Table 225. Research Programs/Design for This Report
Table 226. Authors List of This Report
Table 227. Secondary Sources
Table 228. Primary Sources
List of Figures
Figure 1. PD-1 and PD-L1 Inhibitors Product Picture
Figure 2. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global PD-1 and PD-L1 Inhibitors Market Size Share 2019 VS 2023 VS 2030
Figure 4. PD-1 Inhibitors Picture
Figure 5. PD-L1 Inhibitors Picture
Figure 6. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 7. Global PD-1 and PD-L1 Inhibitors Market Size Share 2019 VS 2023 VS 2030
Figure 8. Solid Tumors Picture
Figure 9. Blood-related Tumors Picture
Figure 10. Global PD-1 and PD-L1 Inhibitors Revenue (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global PD-1 and PD-L1 Inhibitors Revenue (2019-2030) & (US$ Million)
Figure 12. Global PD-1 and PD-L1 Inhibitors Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 13. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region: 2023 Versus 2030
Figure 14. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2019-2030)
Figure 15. Global PD-1 and PD-L1 Inhibitors Sales (2019-2030) & (L)
Figure 16. Global PD-1 and PD-L1 Inhibitors Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (L)
Figure 17. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2019-2030)
Figure 18. US & Canada PD-1 and PD-L1 Inhibitors Sales YoY (2019-2030) & (L)
Figure 19. Europe PD-1 and PD-L1 Inhibitors Sales YoY (2019-2030) & (L)
Figure 20. China PD-1 and PD-L1 Inhibitors Sales YoY (2019-2030) & (L)
Figure 21. Asia (Excluding China) PD-1 and PD-L1 Inhibitors Sales YoY (2019-2030) & (L)
Figure 22. Middle East, Africa and Latin America (Excluding China) PD-1 and PD-L1 Inhibitors Sales YoY (2019-2030) & (L)
Figure 23. Global PD-1 and PD-L1 Inhibitors Manufacturers Revenue Share Top 10 and Top 5 in 2023
Figure 24. Global PD-1 and PD-L1 Inhibitors Manufacturers Sales Share Top 10 and Top 5 in 2023
Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 26. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 27. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type 2019 VS 2023 VS 2030
Figure 28. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2019-2030)
Figure 29. Global PD-1 and PD-L1 Inhibitors Sales by Type (2019 VS 2023 VS 2030) & (L)
Figure 30. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type 2019 VS 2023 VS 2030
Figure 31. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2019-2030)
Figure 32. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 33. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application 2019 VS 2023 VS 2030
Figure 34. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2019-2030)
Figure 35. Global PD-1 and PD-L1 Inhibitors Sales by Application (2019 VS 2023 VS 2030) & (L)
Figure 36. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application 2019 VS 2023 VS 2030
Figure 37. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2019-2030)
Figure 38. North America PD-1 and PD-L1 Inhibitors Revenue Share by Type (2019-2030)
Figure 39. North America PD-1 and PD-L1 Inhibitors Sales Share by Type (2019-2030)
Figure 40. North America PD-1 and PD-L1 Inhibitors Revenue Share by Application (2019-2030)
Figure 41. North America PD-1 and PD-L1 Inhibitors Sales Share by Application (2019-2030)
Figure 42. North America PD-1 and PD-L1 Inhibitors Revenue Share by Country (2019-2030)
Figure 43. North America PD-1 and PD-L1 Inhibitors Sales Share by Country (2019-2030)
Figure 44. Europe PD-1 and PD-L1 Inhibitors Revenue Share by Type (2019-2030)
Figure 45. Europe PD-1 and PD-L1 Inhibitors Sales Share by Type (2019-2030)
Figure 46. Europe PD-1 and PD-L1 Inhibitors Revenue Share by Application (2019-2030)
Figure 47. Europe PD-1 and PD-L1 Inhibitors Sales Share by Application (2019-2030)
Figure 48. Europe PD-1 and PD-L1 Inhibitors Revenue Share by Country (2019-2030)
Figure 49. Europe PD-1 and PD-L1 Inhibitors Sales Share by Country (2019-2030)
Figure 50. China PD-1 and PD-L1 Inhibitors Revenue Share by Type (2019-2030)
Figure 51. China PD-1 and PD-L1 Inhibitors Sales Share by Type (2019-2030)
Figure 52. China PD-1 and PD-L1 Inhibitors Revenue Share by Application (2019-2030)
Figure 53. China PD-1 and PD-L1 Inhibitors Sales Share by Application (2019-2030)
Figure 54. Asia PD-1 and PD-L1 Inhibitors Revenue Share by Type (2019-2030)
Figure 55. Asia PD-1 and PD-L1 Inhibitors Sales Share by Type (2019-2030)
Figure 56. Asia PD-1 and PD-L1 Inhibitors Revenue Share by Application (2019-2030)
Figure 57. Asia PD-1 and PD-L1 Inhibitors Sales Share by Application (2019-2030)
Figure 58. Asia PD-1 and PD-L1 Inhibitors Revenue Share by Country (2019-2030)
Figure 59. Asia PD-1 and PD-L1 Inhibitors Sales Share by Country (2019-2030)
Figure 60. MEALA PD-1 and PD-L1 Inhibitors Revenue Share by Type (2019-2030)
Figure 61. MEALA PD-1 and PD-L1 Inhibitors Sales Share by Type (2019-2030)
Figure 62. MEALA PD-1 and PD-L1 Inhibitors Revenue Share by Application (2019-2030)
Figure 63. MEALA PD-1 and PD-L1 Inhibitors Sales Share by Application (2019-2030)
Figure 64. MEALA PD-1 and PD-L1 Inhibitors Revenue Share by Country (2019-2030)
Figure 65. MEALA PD-1 and PD-L1 Inhibitors Sales Share by Country (2019-2030)
Figure 66. PD-1 and PD-L1 Inhibitors Value Chain
Figure 67. Manufacturing Cost Structure
Figure 68. PD-1 and PD-L1 Inhibitors Production Mode & Process
Figure 69. Direct Comparison with Distribution Share
Figure 70. Distributors Profiles
Figure 71. Years Considered
Figure 72. Research Process
Figure 73. Key Executives Interviewed
